Hans J. Hammers

26.6k total citations · 3 hit papers
216 papers, 8.1k citations indexed

About

Hans J. Hammers is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Hans J. Hammers has authored 216 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 174 papers in Pulmonary and Respiratory Medicine, 119 papers in Oncology and 72 papers in Cancer Research. Recurrent topics in Hans J. Hammers's work include Renal cell carcinoma treatment (157 papers), Cancer Immunotherapy and Biomarkers (86 papers) and Cancer Genomics and Diagnostics (57 papers). Hans J. Hammers is often cited by papers focused on Renal cell carcinoma treatment (157 papers), Cancer Immunotherapy and Biomarkers (86 papers) and Cancer Genomics and Diagnostics (57 papers). Hans J. Hammers collaborates with scholars based in United States, France and Canada. Hans J. Hammers's co-authors include Brian I. Rini, Роберто Пили, David F. McDermott, Elizabeth R. Plimack, Saby George, Robert J. Motzer, Michael A. Carducci, Ian M. Waxman, Martin H. Voss and Asim Amin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Hans J. Hammers

201 papers receiving 8.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

2014 865 citations Robert J. Motzer, Brian I. Rini et al. Journal of Clinical Oncology profile →
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth

2008 520 citations Hans J. Hammers, Роберто Пили et al. profile →
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

2017 348 citations Hans J. Hammers, Elizabeth R. Plimack et al. Journal of Clinical Oncology profile →

Peers

Hans J. Hammers

ONCOL

PRM

IMMUN

Petri Bono Finland

Bruce G. Redman United States

Seiji Yano Japan

Jifeng Feng China

Young Kwang Chae United States

Justin F. Gainor United States

Niels Reinmuth Germany

Sinéad Cuffe Ireland

Kyoichi Kaira Japan

Rafał Dziadziuszko Poland

Petri Bono Finland

Hans J. Hammers

3.9k ×0.9

ONCOL

2.4k ×0.6

PRM

2.7k ×0.9

1.6k ×0.8

1.3k ×1.1

IMMUN

Citations per year, relative to Hans J. Hammers Hans J. Hammers (= 1×) peers Petri Bono

Countries citing papers authored by Hans J. Hammers

Since Specialization

Citations

This map shows the geographic impact of Hans J. Hammers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans J. Hammers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans J. Hammers more than expected).

Fields of papers citing papers by Hans J. Hammers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans J. Hammers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans J. Hammers. The network helps show where Hans J. Hammers may publish in the future.

Co-authorship network of co-authors of Hans J. Hammers

This figure shows the co-authorship network connecting the top 25 collaborators of Hans J. Hammers. A scholar is included among the top collaborators of Hans J. Hammers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans J. Hammers. Hans J. Hammers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bhanvadia, Raj, Isamu Tachibana, Solomon L. Woldu, et al.. (2025). Surgical Outcomes of Radical Nephrectomy and Inferior Vena Cava Thrombectomy Following Preoperative Systemic Immunotherapy: A Propensity Score Analysis. Clinical Genitourinary Cancer. 23(2). 102307–102307. 3 indexed citations

Hammers, Hans J., Payal Kapur, Tianyuan Wang, et al.. (2025). Evaluating Therapeutic Efficacy of the Vascular Disrupting Agent OXi8007 Against Kidney Cancer in Mice. Cancers. 17(5). 771–771. 2 indexed citations

McKay, Rana R., Pedro C. Barata, Moshe Chaim Ornstein, et al.. (2024). 5 A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605. The Oncologist. 29(Supplement_1). S13–S13. 1 indexed citations

Wang, Judy S., David Sommerhalder, Manish Sharma, et al.. (2024). Phase 1/2 study of NGM707, an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation.. Journal of Clinical Oncology. 42(16_suppl). 2582–2582. 2 indexed citations

Mantia, Charlene, Opeyemi A. Jegede, Elizabeth R. Plimack, et al.. (2024). Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214. Journal for ImmunoTherapy of Cancer. 12(7). e009495–e009495. 6 indexed citations

Debnath, Sashi, et al.. (2024). Monovalent and Divalent Designs of Copper Radiotheranostics Targeting Fibroblast Activation Protein in Cancer. Cancers. 16(24). 4180–4180. 2 indexed citations

Atkins, Michael B., Opeyemi A. Jegede, Naomi B. Haas, et al.. (2023). Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). Journal for ImmunoTherapy of Cancer. 11(3). e004780–e004780. 19 indexed citations

Choueiri, Toni K., et al.. (2023). The 5th Kidney Cancer Research Summit: Research Accelerating Cures for Renal Cell Carcinoma in 2023. The Oncologist. 29(2). 91–98. 2 indexed citations

Shah, Neal, Matthew T. Campbell, Shifeng Mao, et al.. (2023). 1889P Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy. Annals of Oncology. 34. S1016–S1017.

10.

Yin, Jianyi, Roy Elias, Lan Peng, et al.. (2022). Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma. Clinical Genitourinary Cancer. 20(3). 260–269. 16 indexed citations

11.

Debnath, Sashi, et al.. (2022). Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Toll-like Receptor 7 Agonists. International Journal of Molecular Sciences. 23(13). 7160–7160. 18 indexed citations

12.

Rini, Brian I., Michael B. Atkins, Elizabeth R. Plimack, et al.. (2021). Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. European Urology Oncology. 5(2). 225–234. 25 indexed citations

13.

Patel, Viral, Roy Elias, William Schwartzman, et al.. (2020). Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 8(2). e001198–e001198. 24 indexed citations

14.

Rini, Brian I., E. Jason Abel, Laurence Albigès, et al.. (2020). Summary from the Kidney Cancer Association’s Inaugural Think Thank: Coalition for a Cure. Clinical Genitourinary Cancer. 19(2). 167–175. 3 indexed citations

15.

Choueiri, Toni K., Michael B. Atkins, Ziad Bakouny, et al.. (2020). Summary From the First Kidney Cancer Research Summit, September 12–13, 2019: A Focus on Translational Research. JNCI Journal of the National Cancer Institute. 113(3). 234–243. 15 indexed citations

16.

Hammers, Hans J., Elizabeth R. Plimack, Jeffrey R. Infante, et al.. (2017). Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. Journal of Clinical Oncology. 35(34). 3851–3858. 348 indexed citations breakdown →

17.

Пили, Роберто, David I. Quinn, Hans J. Hammers, et al.. (2017). Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870). Clinical Cancer Research. 23(23). 7199–7208. 76 indexed citations

18.

Motzer, Robert J., Brian I. Rini, David F. McDermott, et al.. (2014). Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. Journal of Clinical Oncology. 33(13). 1430–1437. 865 indexed citations breakdown →

19.

Isaacs, John T., Lizamma Antony, Susan L. Dalrymple, et al.. (2012). Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment. Cancer Research. 73(4). 1386–1399. 89 indexed citations

20.

Hammers, Hans J., et al.. (2008). Combination of the VEGF receptor tyrosine kinase sunitinib and the mTOR inhibitor rapamycin leads to tumor regression in the RENCA model. Cancer Research. 68. 1104–1104. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact